Faeth Therapeutics
FTH
21 hedge funds and large institutions have $2.38M invested in Faeth Therapeutics in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 2 closing their positions.
0.01% less ownership
Funds ownership: 0.59% → 0.58% (-0.01%)
13% less funds holding
Funds holding: 24 → 21 (-3)
34% less capital invested
Capital invested by funds: $3.58M → $2.38M (-$1.2M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.2K |
| 2 |
Millennium Management
New York
|
+$3.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$29.3K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$13.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.42K |
| 4 |
Renaissance Technologies
New York
|
-$6.12K |
| 5 |
Two Sigma Advisers
New York
|
-$5.91K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Fidelity Investments
Boston,
Massachusetts
| – | -$9 | – | – |
|
FTH Hedge Fund Activity: Q3 2023 in Review
21 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q3 2023, worth a combined $2.38M — down 34% from $3.58M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of FTH and 0 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $41.2K. The largest seller was Newtyn Management, cutting an estimated $29.3K.
- 21 institutional investors held Faeth Therapeutics (FTH) as of Q3 2023, down from 24 in Q2 2023.
- Funds reported $2.38M of Faeth Therapeutics stock for Q3 2023, down 34% quarter-over-quarter.
- 0 funds opened new Faeth Therapeutics positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest Faeth Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $41.2K added.
- The largest Faeth Therapeutics seller in Q3 2023 was Newtyn Management, an estimated $29.3K sold.
Based on aggregated 13F filings for Q3 2023.